Gedeon Richter clarifies safety protocols for Aurobin topical treatment

Gedeon Richter has provided updated clinical guidelines for the use of Aurobin, a topical ointment containing prednisolone, lidocaine, and dexpanthenol. The product is designed to treat inflammatory conditions such as hemorrhoids, anal fissures, and perianal dermatitis.

The pharmaceutical preparation acts by reducing local inflammation, providing anesthetic relief, and supporting tissue repair. Given the hormonal activity of the corticosteroid component, the company advises strictly adhering to medical supervision regarding frequency and duration of application to prevent systemic absorption.

Specific usage constraints apply: the medication is contraindicated for patients under one year of age, during the first trimester of pregnancy, and during breastfeeding. It is also restricted in the presence of various viral, bacterial, or fungal skin infections. Patients experiencing vision changes, skin irritation, or lack of symptom relief are directed to consult a healthcare professional.